Manuela Callari

Experts / Manuela Callari

Science and Medical Writer Sydney

Manuela Callari, PhD, is an award-winning freelance science and medical journalist. She has a PhD in medical science, a bachelor’s and a master’s degree in material science, and a post-graduate degree in science communication.

Obesity drugs: Who will lose weight and for how long?

Which factors predict better outcomes with GLP-1 RAs and their successors...

Diabetes and metabolism, Diet and nutrition

Clinical Articles

Obesity drugs – What’s around the corner

Ozempic has only been approved and funded for lowering blood glucose levels in people with T2D. Wegovy, the higher dose version of semaglutide, has been approved specifically for weight loss, learn more...

Obesity drugs – What’s around the corner

Ozempic has only been approved and funded for lowering blood glucose levels in people with T2D. Wegovy, the higher dose version of semaglutide, has been approved specifically for weight loss, learn more...

By Manuela Callari

Clinical Articles

Diabetes and metabolism, Diet and nutrition

Obesity drugs: Who will lose weight and for how long?

Which factors predict better outcomes with GLP-1 RAs and their successors...

By Manuela Callari

Manuela Callari

Science and Medical Writer Sydney

More from this expert

Obesity drugs: Who will lose weight and for how long?

Which factors predict better outcomes with GLP-1 RAs and their successors...

Obesity drugs – What’s around the corner

Ozempic has only been approved and funded for lowering blood glucose levels in people with T2D. Wegovy, the higher dose version of semaglutide, has been approved specifically for weight loss, learn more...

Obesity drugs – What’s around the corner

Ozempic has only been approved and funded for lowering blood glucose levels in people with T2D. Wegovy, the higher dose version of semaglutide, has been approved specifically for weight loss, learn more...

Obesity drugs: Who will lose weight and for how long?

Which factors predict better outcomes with GLP-1 RAs and their successors...

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Save 50% on all seminars. Hurry, sale ends Dec 31!

You're invited to attend the Women's & Children's Health Update 2026, Australia's most popular seminar for GPs and healthcare professionals. Secure your seat by midnight Dec 31 and save!

Manuela Callari

Science and Medical Writer Sydney

More from this expert

Obesity drugs: Who will lose weight and for how long?

Which factors predict better outcomes with GLP-1 RAs and their successors...

Obesity drugs – What’s around the corner

Ozempic has only been approved and funded for lowering blood glucose levels in people with T2D. Wegovy, the higher dose version of semaglutide, has been approved specifically for weight loss, learn more...

Obesity drugs – What’s around the corner

Ozempic has only been approved and funded for lowering blood glucose levels in people with T2D. Wegovy, the higher dose version of semaglutide, has been approved specifically for weight loss, learn more...

Obesity drugs: Who will lose weight and for how long?

Which factors predict better outcomes with GLP-1 RAs and their successors...

Get the app

Site

Company

Connect

Legal

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Sign up for a free Healthed account

Extra Details

PASSWORD RESET

Discover

Healthed

Save 50% on all seminars. Hurry, sale ends Dec 31!

You're invited to attend the Women's & Children's Health Update 2026, Australia's most popular seminar for GPs and healthcare professionals. Secure your seat by midnight Dec 31 and save!